Marker Therapeutics Inc (MRKR)

[maverick_1]

Feb 25th PR on Dr. BONFIGLIO, MBA; NOW BOD due to his 5 months GUIDING TPIV!

25 Feb2015
TapImmune Appoints John Bonfiglio as Strategic Advisor

Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise

SEATTLE, Feb. 25, 2015 - TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor. John is a highly successful Biotech CEO with broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over $29 million dollars in the public markets while positioning the company for a successful re-listing on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million) and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation’s Immunotherapy Division.

John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.

Not a surprise to me: referenced ALL the key management and strategic advisor additions as pivotal to a totally TRANSFORMED Tapimmune! with recently transferred IP from Mayo Clinic.

BUT this is the penny stock arena (very short term orientation: shr price is back to levels of PH1 data release; acq Mayo IP; $funds for PH@!: end of June! ): OVERDONE on downside and substantially undervalued re RKMatters work!(based on impressive PH1 results: KILLS tumour cells so no re ocurrence: applicable to TNBreast Cancer; Ovarian; melanoma)